These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 7765291)
21. A piece of history. Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894179 [No Abstract] [Full Text] [Related]
22. Targeted therapies: cui prodest? Ferrari D; Foa P J Clin Oncol; 2007 Oct; 25(29):4691-2; author reply 4692. PubMed ID: 17925568 [No Abstract] [Full Text] [Related]
23. Clinical trial development for biosimilars. Alten R; Cronstein BN Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550 [TBL] [Abstract][Full Text] [Related]
24. European Union revamps toxicology testing in attempt to limit animal use, improve prediction. Sinha G J Natl Cancer Inst; 2006 Jun; 98(11):728-9. PubMed ID: 16757693 [No Abstract] [Full Text] [Related]
25. mAb therapeutic products and risk management. Reichert JM MAbs; 2010; 2(1):1-2. PubMed ID: 20065628 [No Abstract] [Full Text] [Related]
26. Industry and regulatory experience of the glycosylation of monoclonal antibodies. Read EK; Park JT; Brorson KA Biotechnol Appl Biochem; 2011; 58(4):213-9. PubMed ID: 21838794 [TBL] [Abstract][Full Text] [Related]
27. United States Food and Drug Administration Regulation of Gene and Cell Therapies. Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210 [TBL] [Abstract][Full Text] [Related]
32. Current regulatory and legal considerations for follow-on biologics. Kingham RF; Lietzan E Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615 [No Abstract] [Full Text] [Related]
33. Regulatory evaluation of biotechnology drugs: current trends in the United States. Sobel S Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148 [No Abstract] [Full Text] [Related]
34. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting]. Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282 [No Abstract] [Full Text] [Related]
35. Definition of a well-characterized biotechnology product. Zoon K; Garnick R Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531 [No Abstract] [Full Text] [Related]
36. Pharmaceutical product integrity: can the FDA assure quality? Bernstein I Manag Care; 2004 Mar; 13(3 Suppl):30-3. PubMed ID: 15074168 [No Abstract] [Full Text] [Related]
37. FDA requires further trials for antiendotoxin monoclonal antibody products. Am J Hosp Pharm; 1992 Aug; 49(8):1848, 1850. PubMed ID: 1442827 [No Abstract] [Full Text] [Related]
38. [Clinical laboratory standardization in the European Community]. Vives Corrons JL Sangre (Barc); 1993 Oct; 38(5):407-11. PubMed ID: 8140506 [No Abstract] [Full Text] [Related]